Italian journal of pediatrics · 2026
Multidisciplinary Delphi Consensus on management of children with moderate-severe atopic dermatitis.
Consensus StatementПисьмо в редакциюНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marseglia Gian Luigi, Tosca Maria Angela, Miraglia Del Giudice Michele, Belloni Fortina Anna, Bonamonte Domenico, Neri Iria, Peroni Diego G, D'Avino Antonio, Comberiati Pasquale, Filippeschi Cesare, Manti Sara, Galli Elena, Mori Francesca, Caffarelli Carlo, Licari Amelia, Ciprandi Giorgio
Аннотация
Atopic dermatitis is a compelling challenge in daily practice. Type 2 inflammation is the most common endotype in children and adolescents with AD. As a result, anti-inflammatory drugs, mainly corticosteroids (CS) and immunomodulatory agents, represent the first-line treatment to dampen type 2 inflammation. However, biologics, particularly dupilumab, dramatically changed the natural history of AD patients. A steering committee composed by expert pediatricians and dermatologists promoted a multidisciplinary Delphi Consensus to improve the knowledge about this topic. Experts in this field participated in the Consensus of three groups of statements concerning definition, diagnosis, and management. There was agreement for all proposed statements. The outcomes of the present multidisciplinary Delphi Consensus propose shared, evidence-based recommendations that may be fruitful in clinical practice.